Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
In this Tools of the Trade article, Dezhong Ji describes the development and use of a chimeric antigenic peptide influenza virus (CAP-Flu) system as a cancer vaccine strategy to promote tumour-infiltrating T cell activation in lung metastasis.
In this Tools of the Trade article, Hongcheng Mai describes the development of wildDISCO, an approach for whole-body immunolabelling, optical clearing and imaging in mice.
In this Tool of the Trade article, Nicolas Mathey-Andrews describes the generation and use of a prime editor mouse that enables in vivo modelling of the multitude of cancer alleles found in human tumours.
Enzymes that produce metabolites specifically required by cancer cells have become attractive targets for therapy. Recently, Doshi et al. highlighted the potential of targeting the detoxifying enzyme UXS1 in cancer.
Kreuzaler et al. examine the spatial metabolic rewiring driven by oncogenic MYC and show that it leads to increased import of vitamin B5, which represents a metabolic vulnerability to tumour progression.
In this study, Bansaccal et al. analyse why, at some skin locations, oncogene-expressing cells rarely progress to cancer and found that a dense dermal collagen network prevents skin cancer formation.
This Review by Elena B. Pasquale outlines the current understanding of Eph receptor–ephrin signalling mechanisms in cancer progression and therapy resistance, and also details therapeutic strategies for targeting the Eph system as a novel cancer therapy and for improving the efficacy of conventional cancer therapies.
In this Review, Mempel et al. use our understanding of the physiological response programmes of the immune system to the more commonplace challenges it encounters as a framework to interpret observations of chemokine function in tumours. When viewed in this way, the design of more effective therapeutic interventions leveraging the chemokine system to recalibrate response patterns to cancer might be possible.
Numerous immunomodulatory antibodies for cancer treatment have been developed following the discovery of negative regulators of antitumour immunity such as programmed cell death protein 1 (PD1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA4). The efficacy of these antibodies is determined not only by their ability to block or engage their target but also by their interactions with Fcγ receptors (FcγRs). This Review outlines our current knowledge of these interactions and discusses how we can use this knowledge to generate more effective cancer immunotherapies in the future.
Targeting platelets represents a promising approach to improve the therapeutic efficacy of chemotherapy and cancer immunotherapy. Here, Li and colleagues highlight the dynamic role of platelets in tumour development, progression, and response to therapy, and underscore the utility of tumour-educated platelets for precise tumour diagnosis and treatment.
